Table 4

Summary of best responses observed with ipilimumab plus nivolumab in metastatic UM

CharacteristicN (%) (95% CI)
CR1 (1)
PR9 (10)
SD21 (24)
PD55 (62)
Not available3 (3)
ORR10/86 (11.6) (5.7 to 20.3)
DCR31/86 (36) (26.0 to 47.1)
Median duration of response6.0 (3.0 to 10.3) months
OS, median, 95% CI15 (10.9 to 21.6) months
PFS, median, 95% CI2.7 (2.6 to 3.3) months
  • CR, complete response; DCR, disease control rate; ORR, overall response rate; OS, overall survival; PD, progression of disease; PFS, progression free survival; PR, partial response; SD, stable disease; UM, uveal melanoma.